Is Jounce Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: JNCE) stock is to Strong Buy JNCE stock.
Out of 2 analysts, 1 (50%) are recommending JNCE as a Strong Buy, 1 (50%) are recommending JNCE as a Buy, 0 (0%) are recommending JNCE as a Hold, 0 (0%) are recommending JNCE as a Sell, and 0 (0%) are recommending JNCE as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year JNCE price target, the average JNCE price target is $4.00, with the highest JNCE stock price forecast at $5.00 and the lowest JNCE stock price forecast at $3.00.
On average, Wall Street analysts predict that Jounce Therapeutics's share price could reach $4.00 by Jan 3, 2024. The average Jounce Therapeutics stock price prediction forecasts a potential upside of 118.58% from the current JNCE share price of $1.83.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.